Y-320

• CAT Number: I002990
• CAS Number: 288250-47-5
• Molecular Formula: C27H29ClN6O2
• Molecular Weight: 505
• Purity: ≥95%
• Target: Interleukin Related
• Solubility: DMSO: ≤ 5.5 mg/mL (Need ultrasonic)
• Storage: 2-8°C
• IC50: 20-60 nM (IL-17 production) [1]
• IUPAC Name: 1-(4-chlorophenyl)-N-[3-cyano-4-(4-morpholin-4-ylpiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide
• InChI: InChI=1S/C27H29ClN6O2/c1-19-25(18-30-34(19)24-5-2-21(28)3-6-24)27(35)31-22-4-7-26(20(16-22)17-29)33-10-8-23(9-11-33)32-12-14-36-15-13-32/h2-7,16,18,23H,8-15H2,1H3,(H,31,35)
• InChIKey: BWZNJVZTAWBIFG-UHFFFAOYSA-N
• SMILES: CC1=C(C=NN1C2=CC=C(C=C2)Cl)C(=O)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCOCC5)C#N

Y-320（Cat No.:I002990） is an orally active immunomodulator that effectively inhibits the production of IL-17, a cytokine involved in inflammatory responses. It achieves this by stimulating the production of IL-15 by CD4 T cells, with IC50 values ranging from 20 to 60 nM. By targeting IL-17 production, Y-320 has the potential to modulate immune responses and mitigate the effects of IL-17-mediated inflammation.

Reference

1:Pharmaceuticals (Basel). 2013 Dec 23;7(1):1-17. doi: 10.3390/ph7010001. A new phenylpyrazoleanilide, y-320, inhibits interleukin 17 production and ameliorates collagen-induced arthritis in mice and cynomolgus monkeys.Ushio H,Ishibuchi S,Oshita K,Seki N,Kataoka H,Sugahara K,Adachi K,Chiba K, PMID: 24366113 PMCID: PMC3915191 DOI: 10.3390/ph7010001 Abstract: Interleukin (IL)-15 and IL-17 are thought to play an important role in the pathogenesis of rheumatoid arthritis (RA) because both pro-inflammatory cytokines are found in synovial fluid of RA patients. In this study, we examined the pharmacological profiles of Y-320, a new phenylpyrazoleanilide immunomodulator. Y-320 inhibited IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM. Oral administration of Y-320 (0.3 to 3 mg/kg) significantly inhibited the development and progression of arthritis and joint destruction with reduction of IL-17 mRNA expression in arthritic joints of type II collagen-induced arthritis (CIA) in DBA/1J mice. Y-320 in combination with anti-murine tumor necrosis factor-α monoclonal antibody showed a synergistic effect on mouse CIA. Moreover, therapeutic treatment with Y-320 (0.3 and 1 mg/kg orally) ameliorated CIA in cynomolgus monkeys. Our results suggest that Y-320, an orally active inhibitor for IL-17 production, provides a useful therapy for RA.